Volitionrx Ltd (NYSE: VNRX)

VolitionRx Limited is a multi-national epigenetics company that develops simple, cost-effective blood tests for the early detection and monitoring of life-altering diseases such as cancer and sepsis. The firm’s proprietary technologies focus on chromosomal structures including nucleosomes and transcription factors as biomarkers in blood samples. VolitionRx Limited’s product portfolio includes the Nu. Q® Vet, Nu. Q® NETs, Nu. Q® Discover, Nu. Q® Cancer, and Capture-Seq™/Capture-PCR™ platforms, which are designed to work in manual, automated, and point-of-care settings. The company operates research, manufacturing, and commercial facilities in Belgium, the United States, and the United Kingdom, supported by a global team of over 75 employees. VolitionRx Limited seeks to improve patient outcomes while reducing healthcare costs through non-invasive blood-based diagnostics.

VolitionRx Limited generates revenue through the sale of diagnostic kits and reagents, licensing of its intellectual property, milestone and royalty payments from partners, and service fees for its Nu. Q® Discover profiling offering. The company sells its Nu. Q® Vet Cancer Test to veterinary distributors such as Antech Diagnostics, IDEXX Laboratories, and Fujifilm Vet Systems, and its Nu. Q® NETs assay to hospital laboratories and clinical institutions. Licensing agreements with firms like Werfen, Hologic, and Revvity provide upfront payments, milestone payments, and ongoing royalties. Additionally, VolitionRx Limited earns revenue from the sale of Capture-Seq™/Capture-PCR™ kits and related components to research and diagnostic partners. The firm also pursues reimbursement pathways for its CE-marked Nu. Q® NETs test and upcoming Nu. Q® Lung Cancer assay to drive recurring sales.

The company operates through the following segments:

• Nu. Q Vet: This segment provides blood-based cancer screening tests for dogs and other companion animals, including the Nu. Q® Vet Cancer Test sold through distributors such as Antech, IDEXX, and Fujifilm Vet Systems, and supports research into feline applications and NETosis detection in canines.

• Nu. Q NETs: This segment offers a CE-marked assay to quantify circulating Neutrophil Extracellular Traps for the detection and monitoring of sepsis and related conditions, compatible with central laboratory and point-of-care workflows.

• Nu. Q Discover: This segment delivers a nucleosome profiling service for drug developers and scientists, enabling epigenetic analysis in disease model development, preclinical testing, and clinical studies.

• Nu. Q Cancer: This segment supplies a range of blood-based assays for cancer screening, diagnosis, therapy selection, treatment monitoring, and minimal residual disease detection, with an initial focus on lung cancer.

• Capture-Seq™/Capture-PCR™: This segment provides a wet chemistry platform that isolates tumor-derived circulating DNA fragments from blood for rapid, cost-effective liquid biopsy analysis using qPCR or sequencing.

VolitionRx Limited occupies a niche within the epigenetics and liquid biopsy markets, competing with larger diagnostics firms such as Exact Sciences, Guardant Health, GRAIL, Natera, Roche Diagnostics, and Thermo Fisher Scientific, while differentiating itself through its focus on nucleosome-based biomarkers, low-cost assay formats, and platform agnostic designs that integrate with existing laboratory equipment. The company’s competitive advantages stem from its broad patent portfolio covering Nucleosomics™, Capture-PCR™, and Capture-Seq™ technologies, its ability to serve both human and veterinary markets, and its strategy of partnering with established diagnostic corporations to leverage their sales and distribution networks.

VolitionRx Limited’s customer base includes veterinary distributors and clinics, hospital laboratories, pharmaceutical and biotechnology companies, and academic research institutions. Specific customers named in the filing are Antech Diagnostics, IDEXX Laboratories, Fujifilm Vet Systems, Vita Genomics, DNA Tech, Nationwide Laboratories, The Veterinary Pathology Group, Heska (now part of Antech), Werfen, Hologic, Revvity, Immunodiagnostic Systems, and the Hospices Civils de Lyon hospital system in France. The company also serves reference laboratories, point-of-care testing sites, and clinical trial sponsors seeking epigenetic profiling services.